|
Age (years), median [IQR]
|
60 [58–63]
|
|
Sex, no. (%)
|
|
M/F
|
46 (85)/8 (15)
|
|
BMI, kg/m2, median [IQR]
|
27 [25.5–28.1]
|
|
Blood pressure (mmHg), median [IQR]
|
|
Systolic
|
130 [120–131.2]
|
|
Diastolic
|
80 [70–80]
|
|
Hypertension, no. (%)
|
15 (28)
|
|
Smoke, no. (%)
|
43 (80)
|
|
Cholesterol (mg/dL), median [IQR]
|
|
Total
|
172 [149.5–189]
|
|
HDL
|
42.5 [35–51]
|
|
LDL
|
103 [68–128]
|
|
Triglycerides (mg/dL), median [IQR]
|
127 [105.2–151.5]
|
|
Glycemia (mg/dL), median [IQR]
|
|
Baseline
|
87 [80–90.2]
|
|
2 h
|
109 [93–126.7]
|
|
Glycated hemoglobin (%), median [IQR]
|
5.2 [5.1–5.5]
|
|
Insulin (µU/mL), median [IQR]
|
3.8 [3–6]
|
|
HOMA IR, median [IQR]
|
0.78 [0.59–1.31]
|
|
Creatinine (mg/dL), median [IQR]
|
1 [0.87–1.1]
|
|
Hemoglobin (mg/dL), median [IQR]
|
14.3 [13.3–15.2]
|
|
Adiponectin (µg/mL), median [IQR]
|
11 [9.7–13.2]
|
|
Adiponectin, no. (%)
|
|
Pathologic
|
13 (24)
|
|
Resistin (ng/mL), median [IQR]
|
7 [4–9]
|
|
Resistin, no. (%)
|
|
Pathologic
|
8 (15)
|
|
TNF-alpha (ng/mL), median [IQR]
|
8.5 [7–11]
|
|
TNF-alpha, no. (%)
|
|
Pathologic
|
6 (11)
|
|
Site of stenosis at first PCI, no. (%)
|
|
IVA
|
25 (46)
|
|
CX
|
10 (19)
|
|
DX
|
19 (35)
|
|
Follow-up duration (months), median [IQR]
|
29.5 [14.7–34]
|
|
Re-PCI, no. (%)
|
4 (7)
|
|
Time re-PCI, median [IQR]
|
8.5 [4–15.75]
|
|
Site of re-PCI, no. (%)
|
|
IVA
|
3 (75)
|
|
CX
|
0 (−)
|
|
DX
|
1 (25)
|
|
New PCI, no. (%)
|
5 (9)
|
|
Time new PCI, median [IQR]
|
29 [IQR 12–33.5]
|
|
Site of new-PCI, no. (%)
|
|
IVA
|
2 (40)
|
|
CX
|
1 (20)
|
|
DX
|
2 (40)
|
|
Death, no. (%)
|
|
Cardiovascular/other causes
|
− /1 (2)
|
